PT  - JOURNAL ARTICLE
AU  - Halem, Michael
TI  - Correcting COVID-19 PCR Prevalence for False Positives in the Presence of Vaccination Immunity
AID  - 10.1101/2021.04.06.21255029
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.06.21255029
4099  - http://medrxiv.org/content/early/2021/04/10/2021.04.06.21255029.short
4100  - http://medrxiv.org/content/early/2021/04/10/2021.04.06.21255029.full
AB  - Many public health authority reports on COVID-19 cases confound positive test results with population prevalence. As the population prevalence approaches the PCR test false positive rate (FPR), for example during a vaccination campaign, it is necessary to adjust the raw test results for the false positive rate. This paper provides a technique for estimating the test false positive rate and making the correction to test population prevalence in the absence of accurate and definitive specificity.Using current data providing by the Public Health England (PHE) as of the most recent complete data, a false positive rate of 1.16% (95% CI 1.09 - 1.23%) was found for the PHE PCR test for the period 1 January through 29 March 2021. During this period, the test population prevalence is decreasing, starting at a decay rate estimated as 3.0% per day (CI 2.79 - 3.14%). This rate of decay increased to an estimated 14.7% by the end of the period (CI 13.30 - 16.16%) Finally, mean test population prevalence was estimated at 14.3% (CI 13.75 - 14.87%) on 1 January and is estimated to have declined significantly to 0.06% (CI 0.00 - 0.13%). If PCR test positivity are used without the application of the false positive rate, the percent positive PCR tests will eventually “flatline” at the false positive rate, and produce a false positive bias even if test population prevalence should fall to zero.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding support. The author did this study independently without funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB - Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and R code is available and will be uploaded to MedRxiv if possible, otherwise will be available on GitHub, including an R function to get the data directly from Public Health England.